Cell Therapeutics making cancer more treatable Making Cancer More Treatable
About CTI making cancer more treatable / Financial History
About CTI Cancer Research, Cancer Therapies, and Cancer Drug Development
Cell Therapeutics Business Strategy
Cell Therapeutics management and cancer drug research & development facilities
Cell Therapeutics Collaborations
Technologies for Cancer Research, Treatment, and Cancer Drug Development
Cell Therapeutics Financial History
Cell Therapeutics Mission & Values
Cell Therapeutics Community Involvement - Helping community organizations that assist people dealing with cancer
CTI Fact Sheet


Since inception, we have funded our operations primarily through the sale of equity and convertible securities.

Year Equity Offerings

Gross Proceeds

1992 Private Placement (equity, common)

$ 38.6 Million

1993 Private Placement (equity, common)

$ 13.8 Million

1995 Private Placement (equity, preferred)

$ 31.9 Million

1996 Private Placement (equity, preferred)

$ 22.0 Million

1997
Initial Public Offering

$ 30.0 Million

1997 Private Placement (equity, common)
$3.0 Million
1997 Follow-on Offering

$ 36.8 Million

1999 Private Placement (equity, preferred)

$ 10.0 Million

2000 Private Placement (equity, common)

$ 40.0 Million

2000 Private Placement (equity, common)
$ 136.8 Million
2001 Private Placement (debt, was $175 M convertible, a portion of these notes were converted to new notes in 2002)
$ 175.0 Million
2002 Convertible debt exchange ($145.6 M convertible notes issued in 2001 were exchanged for $85.5 M new notes)
--
2003 Convertible Senior Subordinated Notes Offering
$75.0 Million
2004 Follow-on offering (common)
$49.2 Million
2004 Direct Equity Placement
$18.4 Million
2005 Convertible Senior Notes Offering (Exchanged $38.4 million in notes through conversion and placement agreement)
$82.0 Million
2006 Convertible Senior Notes
$33.2 Million
2006 Exchanged $40.7 million of existing notes for $33.2 million of new notes
2006 Registered Offering of Common Stock

$40.0 Million

2006 Securities Purchase Agreement (Novartis)
$15.0 Million
2007 Convertible Preferred Stock and Warrants
$20.0 Million
2007 Convertible Preferred Stock and Warrants
$37.2 Million
2007 Convertible Preferred Stock and Warrants
$20.25 Million
2007 Convertible Preferred Stock and Warrants
$6.5 Million
2007

Debt exchange [exchanged $36.1 Million in debt ($10.5 M of 5.75% subordinated senior notes and $25.6 M of 5.75% subordinated notes, both due in June 2008) for $23.25 Million in new 5.75% senior notes (due in December 2011) plus 5,459,574 shares of common stock]

 
2007

Direct offering (issued 3,469,999 shares of common stock and warrants to purchase an additional 3,469,999 shares of common stock for approximately $7 M in gross proceeds)

 
2008

Société Générale offering (common)

$1.27 Million
2008 Convertible debt exchange (exchanged $9.1 Million existing notes for 6.85 million shares of common stock)  


Posted March 4, 2008

Copyright © 2004-2008 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is a registered mark of CTI.